{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T10:07:55Z","timestamp":1784196475733,"version":"3.55.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","endocrinologydiabetes.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["AACE Endocrinology and Diabetes"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.aed.2026.03.013","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T23:34:12Z","timestamp":1776468852000},"page":"633-637","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Persistent Adrenocortical Insufficiency After Long-Term Metyrapone Treatment for Cushing\u2019s Disease"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-2837-7355","authenticated-orcid":false,"given":"Satoshi","family":"Yamagata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah M.","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takefumi","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shojiro","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Kageyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.aed.2026.03.013_bib1","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/j.1365-2265.2004.02115.x","article-title":"Cavernous and inferior petrosal sinus sampling in the evaluation of ACTH-dependent Cushing\u2019s syndrome","volume":"61","author":"Liu","year":"2004","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.aed.2026.03.013_bib2","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1056\/NEJM199109263251301","article-title":"Petrosal sinus sampling with and without corticotropin-releasing hormone for the differential diagnosis of Cushing\u2019s syndrome","volume":"325","author":"Oldfield","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.aed.2026.03.013_bib3","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40267-021-00853-y","article-title":"Metyrapone in Cushing\u2019s syndrome: a profile of its use","volume":"37","author":"Al-Salama","year":"2021","journal-title":"Drugs Ther Perspect"},{"key":"10.1016\/j.aed.2026.03.013_bib4","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1210\/jc.2015-2616","article-title":"Effectiveness of metyrapone in treating Cushing\u2019s syndrome: a retrospective multicenter study in 195 patients","volume":"100","author":"Daniel","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.aed.2026.03.013_bib5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.clinbiochem.2010.07.008","article-title":"Liquid chromatography tandem mass spectrometry for analysis of steroids in clinical laboratories","volume":"44","author":"Kushnir","year":"2011","journal-title":"Clin Biochem"},{"key":"10.1016\/j.aed.2026.03.013_bib6","doi-asserted-by":"crossref","first-page":"M33","DOI":"10.1530\/EJE-15-0464","article-title":"Cushing\u2019s syndrome: update on signs, symptoms and biochemical screening","volume":"173","author":"Nieman","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.aed.2026.03.013_bib7","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/19714009221126016","article-title":"Central venous sampling and magnetic resonance imaging in the diagnosis of ACTH-dependent Cushing\u2019s syndrome","volume":"36","author":"Aydo\u011fan \u00dcnsal","year":"2023","journal-title":"Neuroradiol J"},{"key":"10.1016\/j.aed.2026.03.013_bib8","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s12020-018-1675-4","article-title":"Metyrapone treatment in Cushing\u2019s syndrome: a real-life study","volume":"62","author":"Ceccato","year":"2018","journal-title":"Endocrine"},{"key":"10.1016\/j.aed.2026.03.013_bib9","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1258\/acb.2011.011014","article-title":"Comparison of serum cortisol measurement by immunoassay and liquid chromatography-tandem mass spectrometry in patients receiving the 11\u03b2-hydroxylase inhibitor metyrapone","volume":"48","author":"Monaghan","year":"2011","journal-title":"Ann Clin Biochem"},{"key":"10.1016\/j.aed.2026.03.013_bib10","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1210\/jc.2015-1818","article-title":"Treatment of Cushing\u2019s syndrome: an Endocrine Society Clinical Practice guideline","volume":"100","author":"Nieman","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.aed.2026.03.013_bib11","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/ejendo\/lvaf181","article-title":"Prospective study of metyrapone in endogenous Cushing's syndrome (PROMPT)","volume":"193","author":"Nieman","year":"2025","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.aed.2026.03.013_bib12","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1258\/acb.2011.011207","article-title":"Comparison of serum cortisol measurement by immunoassay and liquid chromatography-tandem mass spectrometry in patients receiving the 11\u03b2-hydroxylase inhibitor metyrapone","volume":"49","author":"Halsall","year":"2012","journal-title":"Ann Clin Biochem"},{"key":"10.1016\/j.aed.2026.03.013_bib13","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1258\/acb.2010.010167","article-title":"Cortisol measurement in patients receiving metyrapone therapy","volume":"47","author":"Owen","year":"2010","journal-title":"Ann Clin Biochem"},{"key":"10.1016\/j.aed.2026.03.013_bib14","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0960-0760(97)00027-7","article-title":"Metyrapone is a competitive inhibitor of 11\u03b2-hydroxysteroid dehydrogenase type 1 reductase","volume":"62","author":"Sampath-Kumar","year":"1997","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.aed.2026.03.013_bib15","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1210\/jcem-42-4-687","article-title":"Dual sites of inhibition by metyrapone of human adrenal steroidogenesis: correlation of in vivo and in vitro studies","volume":"42","author":"Carballeira","year":"1967","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.aed.2026.03.013_bib16","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0008-6363(98)00230-2","article-title":"The role of corticosteroids in the regulation of vascular tone","volume":"41","author":"Ullian","year":"1999","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.aed.2026.03.013_bib17","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014950","article-title":"Glucocorticoids reverse diluted hyponatremia through inhibiting arginine vasopressin pathway in heart failure rats","volume":"9","author":"Zhu","year":"2020","journal-title":"J Am Heart Assoc"}],"container-title":["AACE Endocrinology and Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050915726000731?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050915726000731?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T09:37:05Z","timestamp":1784194625000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3050915726000731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S3050915726000731"],"URL":"https:\/\/doi.org\/10.1016\/j.aed.2026.03.013","relation":{},"ISSN":["3050-9157"],"issn-type":[{"value":"3050-9157","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Persistent Adrenocortical Insufficiency After Long-Term Metyrapone Treatment for Cushing\u2019s Disease","name":"articletitle","label":"Article Title"},{"value":"AACE Endocrinology and Diabetes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aed.2026.03.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Association of Clinical Endocrinology.","name":"copyright","label":"Copyright"}]}}